Loading market dashboard
Tyra Biosciences, Inc.
TYRAHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer- CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the establishment of Upper Tract Urothelial Cancer (UTUC) Awareness Day, in collaboration with the Bladder Cancer Advocacy Network (BCAN).
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 - - Initial Ph2 data readout from SURF302 expected in August 2026 (n>20 enrolled to date) - - Initial Ph2 data readout from safety sentinel cohort in BEACH301 expected in Q4 2026 (4th dose level cleared) - - Cash, cash equivalents and marketable securities of $383.5 million at Q1 2026; runway into 2H 2028 - CARLSBAD, Calif., May 13, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress.
CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences: BofA Securities Health Care Conference 2026 Format: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, May 13, 2026 at 10:40 am PTLocation: Las Vegas, NV TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Format: Fireside chat with Tyler van BurenPresentation Date/Time: Tuesday, May 26, 2026 at 2:00 pm ETLocation: Virtual Jefferies Global Healthcare Conference Format: Hybrid fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, June 3, 2026 at 3:45 pm ETLocation: New York, NY A live webcast of the presentations can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.
Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the twelve ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy
-Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth- CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment of Habib Dable to its Board of Directors.
Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) Director Gilla Kaplan sold 14,295 shares of the firm's stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director directly owned 28,231 shares of the company's
Boone Capital added 398,482 shares of TYRA in the fourth quarter. The quarter-end position value rose by $10.48 million as a result of the new stake.
